drugset / Trial / NCT00580606

A Randomized, Double-Blind Placebo-Controlled Peanut Sublingual Immunotherapy Trial

NCT00580606 ↗

RandomizedCrossoverTriple-blindTreatment

Summary

The purpose of this study is to evaluate the safety and immune response to daily sublingual (under the tongue) immunotherapy (SLIT) with peanut extract in adults and children with peanut allergies.

Timeline

Start
2007-12
Primary completion
2010-12
Completion
2014-12

Outcome

Met primary endpoint

registry Low Dose Peanut SLIT (Double Blind) vs Placebo (Double Blind); p <0.001; Risk Difference (RD) 55 (95% CI 22.2 to 77.6) NCT00580606 ↗

Drugs

EvaluationDrugModalityDoseRoute
Subject Glycerinated peanut allergenic extract Unknown 165 ug Other
Subject Glycerinated peanut allergenic extract Unknown 1386 ug Other
Subject Glycerinated peanut allergenic extract Unknown 3696 ug Other

Indications